Lynn W Maines

Targepeutics, Inc.

$5,085,429

Attributed

$5,085,429

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.8M · FY2005–14

$2M$1.5M$1M$500K$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

Funding mix

By agency

NIH$4,885,429 · 7

FDA$200,000 · 1

By mechanism

R44$3,569,212 · 2

R43$1,316,217 · 5

R01$200,000 · 1

Top collaborators

No co-investigators on record.

Others in their field

Top investigators on “In Vivo Model”

David Heimbrook · Leidos Biomedical Research, Inc.$345,981,914
Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
Dennis R. Burton · Scripps Research Institute$216,575,541
Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
Richard C Boucher · University Of North Carolina Chapel Hill$76,063,312
Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714

Research focus

In Vivo ModelTnf GeneSafetyPharmaceutical PreparationsInhibitor/AntagonistToxicologyToxic EffectSphingosine KinaseSphingosine 1-PhosphateSphingolipidsClinical TrialsChronicInnovationTumor Necrosis Factor-AlphaEventResponseProgramsMetabolismAnimalsMolecular TargetKinase InhibitorMediatingTherapeutic AgentsAttenuated